Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -35.50% is 74% above its 5-year average of -134.72%, near the high end of its 5-year range (-437.57%–-10.09%).
96.40% below its 12-month average of -18.07%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.83%.
RETURN ON ASSETS (ROA)
-35.50%
RETURN ON ASSETS (ROA) AVG TTM
-18.07%
RETURN ON ASSETS (ROA) AVG 3Y
-62.20%
RETURN ON ASSETS (ROA) AVG 5Y
-134.72%
RETURN ON ASSETS (ROA) AVG 10Y
-108.75%
RETURN ON ASSETS (ROA) AVG 15Y
-95.51%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-96.40%
CURRENT VS 3Y AVG
+42.92%
CURRENT VS 5Y AVG
+73.65%
CURRENT VS 10Y AVG
+67.36%
CURRENT VS 15Y AVG
+62.83%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-10.03%
vs the sector median at left
LifeMD, Inc.
Market Cap
$159.22M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
Market Cap
$159.14M
Return on Assets (ROA)
-68.50%
TTM Avg
-29.78%
3Y Avg
-39.51%
5Y Avg
-30.76%
Market Cap
$159.78M
Return on Assets (ROA)
-50.88%
TTM Avg
-55.59%
3Y Avg
-49.48%
5Y Avg
-39.11%
Market Cap
$159.80M
Return on Assets (ROA)
-414.72%
TTM Avg
-147.82%
3Y Avg
-101.66%
5Y Avg
-78.00%
Market Cap
$162.04M
Return on Assets (ROA)
-38.52%
TTM Avg
-17.54%
3Y Avg
-16.16%
5Y Avg
-14.54%
Market Cap
$156.22M
Return on Assets (ROA)
-8.61%
TTM Avg
-9.87%
3Y Avg
-17.96%
5Y Avg
-12.40%
Market Cap
$153.79M
Return on Assets (ROA)
-23.14%
TTM Avg
-29.29%
3Y Avg
-29.10%
5Y Avg
-28.90%
Market Cap
$153.58M
Return on Assets (ROA)
N/A
TTM Avg
-34.95%
3Y Avg
-49.76%
5Y Avg
-43.08%
Market Cap
$165.27M
Return on Assets (ROA)
-34.75%
TTM Avg
-23.73%
3Y Avg
-25.63%
5Y Avg
-26.84%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMDP) | $159.22M | -35.50% | -18.07% | -62.20% | -134.72% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -68.50% | -29.78% | -39.51% | -30.76% |
| PepGen Inc. (PEPG)vs › | $159.78M | -50.88% | -55.59% | -49.48% | -39.11% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | -414.72% | -147.82% | -101.66% | -78.00% |
| Quanterix Corporation (QTRX)vs › | $162.04M | -38.52% | -17.54% | -16.16% | -14.54% |
| Inogen, Inc. (INGN)vs › | $156.22M | -8.61% | -9.87% | -17.96% | -12.40% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -23.14% | -29.29% | -29.10% | -28.90% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | -34.95% | -49.76% | -43.08% |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -34.75% | -23.73% | -25.63% | -26.84% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 2.80% | -4.42% | -6.73% | -5.05% |
ROA
-35.5%
ROE
-266.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -10.09% |
| 2024-12-31 | -26.06% |
| 2023-12-31 | -35.22% |
| 2022-12-31 | -177.42% |
| 2021-12-31 | -121.98% |
| 2020-12-31 | -437.57% |
| 2019-12-31 | -91.03% |
| 2018-12-31 | -47.43% |
| 2017-12-31 | -95.42% |
| 2016-12-31 | -140.23% |
| 2015-12-31 | -13.82% |
| 2014-12-31 | -262.80% |
| 2013-12-31 | -48.65% |
| 2012-12-31 | -120.55% |
| 2011-12-31 | -146.49% |
